Comprehensive Quality Care in Kidney Diseases and Hypertension in Western Australia

Resume- Dynamic

CURRENT POSITIONS:

  • Head of Department – Armadale Renal Services – Armadale Health Services WA June 2004 – till date
  • Renal Physician – Royal Perth Hospital and Health Services (Post reconfiguration of Health Services): Feb 2015 – till date
  • Renal Physician – St John of God Health Care (Murdoch): Jun 2004 till date
  • Renal Physician: Mount Hospital – June 2004 – till date.
  • Dobney Hypertension Centre, Medical Research Foundation, Royal Perth Hospital, Perth.
  • Linear Research Institute, Nedlands.

RECENT POSITIONS:

  • Renal Physician – Peel Health Campus (Mandurah)- June 2004 till date
  • Co –Clinical Lead, Renal Health Network, Health Networks Branch, Dept of Health, WA 2012 – till Jun 2020
  • Renal Physician – Fremantle Hospital and Health Services June 2004 – Jan 2015

GRANTS & AWARDS:

  • Feb 2014: Assoc Investigator for NHMRC Grant ($ 1 million) for Feb 2014: APP1079502 Chronic Kidney Disease Centre of Research Excellence https://cre-ckd.centre.uq.edu.au/profile/95/hemant-kulkarni
  • June 2013: Kidney Health Australia: OPERATION ANGEL Award: For Inspirational Contribution to the patients with Kidney Care in Western Australia
  • 2012- 2013: ANZSN-Amgen Quality Assurance Grant ($ 10,000) for assessment of the development of Vascular access centre in Outer Metropolitan Hospital
  • 2007: ANZSN- NEPHROLOGY RESEARCH GRANT ($ 35,000) for clinical research in Iron Overload in Haemodialysis population
  • 1997: First Rank in University of Mumbai for DM (Nephrology) examination
  • Dec 1994: Pfizer Postgraduate Medical Award & Medallion & Scroll of honour for securing highest marks in Medicine in MBBS
  • 1990-1991: N F Surveyor Gold Medal for 1ts Rank in MBBS at Grant Medical College, University of Mumbai
  • March 1991: Prof M B Gharpure Memorial Prize (1st in Pharmacology) at Grant Medical College, University of Mumbai
  • Merit awards and Scholarships by Govt of India and Maharashtra: HSC certification

QUALIFICATIONS:

  • 2003: FRACP: Royal Australasian College of Physicians
  • 2002: AMC: Australasian Medical Council Examinations
  • 1999: MRCPCH (UK): Royal College of Physicians, United Kingdom
  • 1997: DM (NEPHROLOGY): Doctor of Medicine, University of Mumbai, India (!st rank in Univ of Mumbai)
  • 1995: MD (PEDIATRICS): Doctor of Medicine, University of Mumbai, India
  • 1994: DCH: College of Physicians and Surgeons, Mumbai, India
  • 1992: MBBS : Grant Medical College, University of Mumbai, India (1st rank in Grant Medical College)

PUBLICATIONS:

RESEARCH GATE: https://www.researchgate.net/profile/Hemant_Kulkarni2/publications

Public URL for Google Scholar http://scholar.google.com.au/citations?user=gRzjH2wAAAAJ

  • Peter Kolovos, Christopher E Davies, Feruza Kholmurodova, Georgina Irish, Hemant Kulkarni, …., Solomon Menahem. Risk factors associated with 30-day mortality following COVID-19 infection in patients receiving kidney replacement therapy in Australian and New Zealand.: Submitted to CKJ June 2024
  • Light C, Heslop K, Kulkarni H. Comparison of Factors Affecting the Immune Response to Hepatitis B Vaccination in Patients with Stage 5 Chronic Kidney Disease-haemodialysis and Predialysis. Open Urol Nephrol J, 2024; 17: e1874303X304324. ttp://dx.doi.org/10.2174/011874303X304324240529133609
  • Updated results from the RUBY-3 study of Povetaciciept, an enhanced dual BAFF/APRIL antagonist in Autoantibody associated glomerulonephritis. Kidney International Reports, Vol 9 (4), S 505 (April 2024)
    Povetaciciept, an enhanced dual BAFF/APRIL antagonist in Autoantibody associated glomerulonephritis. Kidney International Reports, Vol 9 (4), S-141 (April 2024)
  • Updated results from the RUBY-3 study of Povetaciciept, an enhanced dual BAFF/APRIL antagonist in Autoantibody associated glomerulonephritis. NDT (Neph Dial Transp Vol 39, Issue Supplement 1, 0431- (May 2024)
  • Prophylactic antibiotics before insertion of tunneled hemodialysis catheters: A Nationwide Cohort Study. Benjamin Lazarus et al on behalf of the REDUCCTION investigators – Submitted to JASN.
  • Younger adults were disproportionately affected by hemodialysis catheter infections in Australia: A Prospective Nationwide Cohort Study. Benjamin Lazarus et al on behalf of the REDUCCTION investigators – Submitted to JASN
  • Replacement Strategies for Tunnelled Hemodialysis Catheters with Complications: A Nationwide Cohort Study Benjamin Lazarus et al on behalf of the REDUCCTION investigators – Submitted to JASN
  • Casey Light, Karen Heslop, HEMANT KULKARNI: Hepatitis B vaccination in patients with stage 4/5 chronic kidney disease – a scoping review. Renal Society of Australasia Journal 2023; 19(1):68-76.
  • Smyth, B., Kotwal, S., Gallagher, M., Gray, N. A., & Polkinghorne, K. (2018). Dialysis catheter management practices in Australia and New Zealand. Nephrology (Carlton). 2018 Sep 28. . Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30267459. doi:10.1111/nep.13507
  • Light C; Kulkarni H (Mar 2018). Booster hepatitis B vaccination in haemodialysis patients: Five-year prospective observational study Renal Society of Australasia Journal
  • Holman, R, Olynyk, JK, Kulkarni, H and Ferrari, P (2017), Characterisation of hepatic and cardiac iron deposition during standard treatment of anaemia in haemodialysis. Nephrology, Feb 2017, doi: 10.1111/nep.12735.
  • SD Roger, CA Gaillard, AH Bock, F Carrera…H Kulkarni (As Investigator Group)… et al. Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial. Nephrology Dialysis Transplantation, 2016 doi: 10.1093/ndt/gfw264
    Hoy, W. E., H. G. Healy, D. Waugh, M. D. Jose, H. Kulkarni, I. Katz, C. Nelson, K. Panaretto, and R. Walker. “Towards a national surveillance network for chronic kidney disease (CKD).” In Nephrology, vol. 19, pp. 58-88. 2014.
    AL Graves, M Texler, L Manning, H Kulkarni. Successful treatment of renal allograft and bladder malakoplakia with minimisation of immunosuppression and prolonged antibiotic therapy. Nephrology, Vol 19, Suppl 1, 18-21, April 2014.
    H Kulkarni, N Lenzo, A McLean‐Tooke. Causality of rhabdomyolysis and combined tetanus, diphtheria and acellular pertussis (Tdap) vaccine administration. The Journal of Clinical Pharmacology 53 (10), 1099-1102, 2013
    DW Johnson, FG Brown, M Clarke, N Boudville, TJ Elias, MWY Foo, B Jones, H Kulkarni.. Et al…
    The Effects of Biocompatible Compared with Standard Peritoneal Dialysis Solutions on Peritonitis Microbiology, Treatment, and Outcomes: the balANZ Trial
    Peritoneal Dialysis International 32 (5), 497-506 ; 2012DW
    Johnson, FG Brown, M Clarke, N Boudville, TJ Elias, MWY Foo, B Jones, H Kulkarni.. Et al…
    Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes J Am Soc Nephrol 23, 1097-1107 , 2012
    DW Johnson, FG Brown, M Clarke, N Boudville, TJ Elias, MWY Foo, B Jones, H Kulkarni.. Et al…
    The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial
    Nephrology Dialysis Transplantation. 2012
    Ferrari P, Kulkarni H, Dheda S, Betti S, Harrison C, St. Pierre T, and Olynyk J. Serum Iron Markers Are Inadequate for Guiding Iron
    Repletion in Chronic Kidney Disease Clin J Am Soc Nephrol Jan 2011 (Published online on September 28, 2010 as doi:10.2215/CJN.04190510)
    Clark BM, Boan P, Kulkarni H. A Case of Legionella longbeachae Pneumonia Complicated by Rhabdomyolysis and Acute Renal Failure Requiring Hemodialysis. Infectious Diseases in Clinical Practice. 18(6):413-416, November 2010.
    JK Olynyk, P Ferrari, H Kulkarni, TC Tan, D Trinder.
    Non-invasive characterisation of significant hepatic iron overload in hyperferritinemic subjects HEPATOLOGY, Vol 48, Issue 4, 1170A, 2008
    Singer R, Rhodes H, Chin G, Kulkarni H, Ferrari P. High prevalence of ascorbate deficiency in an Australian peritoneal dialysis population. Nephrology (Carlton), 2008: Volume 13 Issue 1 Page 17-22.Howman H, Kulkarni H. Antibody-mediated acquired Pure Red Cell Aplasia after treatment with darbepoetin – Nephrology Dialysis Transplantation 2007 22(5):1462-1464.
    Thomas MA, Luxton G, Moody HR, Woodroffe AJ, Kulkarni H, Lim W, Christiansen FT, Opelz G. Subjective and quantitative assessment of patient fitness for cadaveric kidney transplantation: the “equity penalty”. Transplantation. 2003 Apr 15;75(7):1026-9.
    H Kulkarni, K Jureidini, P Trnka, P Henning, R Vigneswaran, S Harris
    Cystatin C is a promising marker of renal function in newborns during first 3 months. Nephrology Dialysis Transplantation 18 (18 (suppl 4): 808-813.), 808-813 2003 Playford D, Kulkarni H, Thomas M, Vivian J, Low A, Mander J, Perlman D, Finch P. Intra-ureteric capsaicin in loin pain haematuria syndrome: efficacy and complications. British Journal of Urology Int. 2002 Oct;90(6):518-21. Kulkarni H, Goldwater PN, Martin A, Bettelheim KA. Escherichia coli ‘O’ group serological responses and clinical correlations in epidemic HUS patients. Comp Immunol Microbiol Infect Dis. 2002 Jul;25(4):249-68.
    H Kulkarni, S Bichu, U Oza, A Kirpalani. Sulphonamide crystalluria induced acute renal failure in a renal allograft. —A case report,
    Indian Journal of Nephrology, Vol 7, No 1, 20-21, Jan-Mar 1997.
    Patnekar PN, Kulkarni HA, Khopkar SR, Kulkarni VS, Nerurkar RS. Nevus flammeus in tuberous sclerosis Indian Pediatr. 1995 Sep;32(9):1038-9.
    H KULKARNI: Antiphospholipid Syndrome in a single kidney- A case report: Indian Journal of Renal Sciences, 1999.
    H KULKARNI: Can Cystatin C replace creatinine as a marker of renal function? Review article in Indian Journal of Renal Sciences, 1999.

CURRENT TRIALS:

Hepatitis B Vaccination in Advanced CKD – Stage 4 v/s Stage 5

The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD (MRI and Echo Substudy) https://classic.clinicaltrials.gov/ct2/show/NCT05374291

Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial) (ZENITH-CKD) – https://classic.clinicaltrials.gov/ct2/show/NCT04724837

RUBY – 3 Trial – IgA (Closed for recruitment); SLE; Memb GN (Closed for recruitment), ANCA associated vasculitis:
Impressive results with auto antibody reduction
https://www.alpineimmunesciences.com/wp-content/uploads/2024/04/WCN-2024-RUBY-3-LB-poster_FINAL.pdf

ALXN1210-IgAN-320: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN): IgA Nephropathy with proteinuria and biopsy

PHOSPHATE Study – Recruitment closed and followup extended for another 2 years (2026)

BEAT – CALCI TRIAL: Calciphylaxis on dialysis (Started – August 2024)